These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 28625716)

  • 61. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M; Tanaka T; Nangaku M
    Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
    Fukuta H; Hagiwara H; Kamiya T
    PLoS One; 2022; 17(9):e0275311. PubMed ID: 36170343
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis.
    Pan SY; Tsai PZ; Chou YH; Chang YT; Chang FC; Chiu YL; Chiang WC; Hsu T; Chen YM; Chu TS; Lin SL
    Kidney Int; 2021 Jun; 99(6):1354-1368. PubMed ID: 33812664
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [(4-Hydroxyl-benzo[4,5]thieno[3,2-c]pyridine-3-carbonyl)-amino]-acetic acid derivatives; HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues.
    Hong YR; Kim HT; Lee SC; Ro S; Cho JM; Kim IS; Jung YH
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5953-7. PubMed ID: 24042008
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of prolyl-hydroxylase inhibition and chronic intermittent hypoxia on synaptic transmission and plasticity in the rat CA1 and dentate gyrus.
    Wall AM; Corcoran AE; O'Halloran KD; O'Connor JJ
    Neurobiol Dis; 2014 Feb; 62():8-17. PubMed ID: 24055213
    [TBL] [Abstract][Full Text] [Related]  

  • 66. EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis.
    Kobayashi H; Davidoff O; Pujari-Palmer S; Drevin M; Haase VH
    Acta Physiol (Oxf); 2022 Aug; 235(4):e13826. PubMed ID: 35491502
    [TBL] [Abstract][Full Text] [Related]  

  • 67. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.
    Wakashima T; Tanaka T; Fukui K; Komoda Y; Shinozaki Y; Kobayashi H; Matsuo A; Nangaku M
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F14-F24. PubMed ID: 31630548
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors.
    Yap DYH; McMahon LP; Hao CM; Hu N; Okada H; Suzuki Y; Kim SG; Lim SK; Vareesangthip K; Hung CC; Nangaku M;
    Nephrology (Carlton); 2021 Feb; 26(2):105-118. PubMed ID: 33222343
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibition of transforming growth factor β1/Smad3 signaling decreases hypoxia-inducible factor-1α protein stability by inducing prolyl hydroxylase 2 expression in human periodontal ligament cells.
    Watanabe T; Yasue A; Tanaka E
    J Periodontol; 2013 Sep; 84(9):1346-52. PubMed ID: 23088526
    [TBL] [Abstract][Full Text] [Related]  

  • 70. β-N-oxalyl-L-α, β- diaminopropionic acid induces HRE expression by inhibiting HIF-prolyl hydroxylase-2 in normoxic conditions.
    Eslavath RK; Sharma D; Bin Omar NAM; Chikati R; Teli MK; Rajanikant GK; Singh SS
    Eur J Pharmacol; 2016 Nov; 791():405-411. PubMed ID: 27393459
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Oxygen sensors as therapeutic targets in kidney disease.
    Haase VH
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S29-S34. PubMed ID: 28577740
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Retinoic acid regulates erythropoietin production cooperatively with hypoxia-inducible factors in human iPSC-derived erythropoietin-producing cells.
    Katagiri N; Hitomi H; Mae SI; Kotaka M; Lei L; Yamamoto T; Nishiyama A; Osafune K
    Sci Rep; 2021 Feb; 11(1):3936. PubMed ID: 33594180
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Significance of prolyl hydroxylase 2 in the interference of aryl hydrocarbon receptor and hypoxia-inducible factor-1 alpha signaling.
    Seifert A; Katschinski DM; Tonack S; Fischer B; Navarrete Santos A
    Chem Res Toxicol; 2008 Feb; 21(2):341-8. PubMed ID: 18072750
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Selective inhibition of the hypoxia-inducible factor prolyl hydroxylase PHD3 by Zn(II).
    Na YR; Woo DJ; Choo H; Chung HS; Yang EG
    Chem Commun (Camb); 2015 Jul; 51(53):10730-3. PubMed ID: 26051901
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The roles and signaling pathways of prolyl-4-hydroxylase 2 in the tumor microenvironment.
    Li A; Zhang Y; Wang Z; Dong H; Fu N; Han X
    Chem Biol Interact; 2019 Apr; 303():40-49. PubMed ID: 30817904
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Integrity of the prolyl hydroxylase domain protein 2:erythropoietin pathway in aging mice.
    Li X; Sutherland S; Takeda K; Fong GH; Lee FS
    Blood Cells Mol Dis; 2010 Jun; 45(1):9-19. PubMed ID: 20400342
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells.
    Rauner M; Franke K; Murray M; Singh RP; Hiram-Bab S; Platzbecker U; Gassmann M; Socolovsky M; Neumann D; Gabet Y; Chavakis T; Hofbauer LC; Wielockx B
    J Bone Miner Res; 2016 Oct; 31(10):1877-1887. PubMed ID: 27082941
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
    Joharapurkar AA; Pandya VB; Patel VJ; Desai RC; Jain MR
    J Med Chem; 2018 Aug; 61(16):6964-6982. PubMed ID: 29712435
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pyrithione Zn selectively inhibits hypoxia-inducible factor prolyl hydroxylase PHD3.
    Na YR; Woo DJ; Kim SY; Yang EG
    Biochem Biophys Res Commun; 2016 Apr; 472(2):313-8. PubMed ID: 26940742
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association.
    Stoumpos S; Crowe K; Sarafidis P; Barratt J; Bolignano D; Del Vecchio L; Małyszko J; Więcek A; Ortiz A; Cozzolino M
    Nephrol Dial Transplant; 2024 Sep; 39(10):1710-1730. PubMed ID: 38573822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.